CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent

EarningsNeutral
AI Analysis

Summary

Johnson & Johnson reported Q3 2026 earnings in line with expectations, driven by innovative medicines, though medtech underperformed and newer medicines failed to contribute materially.

Importance:3/10
Sentiment:
0.00
Q3 2026 earningsinnovative medicinesmedtech disappointmentlegacy products
Related Companies

Read the original article

Published by BioSpace on October 13, 2026 3:20 PM

Read Original